VARICELLA ZOSTER VIRUS--T CELL/SKIN TROPISMS AND IMMUNIT
水痘带状疱疹病毒--T细胞/皮肤向性和免疫
基本信息
- 批准号:6532668
- 负责人:
- 金额:$ 29.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1994
- 资助国家:美国
- 起止时间:1994-08-01 至 2004-06-30
- 项目状态:已结题
- 来源:
- 关键词:Herpesviridae vaccine MHC class I antigen MHC class II antigen SCID mouse T lymphocyte antigen presentation cell migration cellular immunity chickenpox epitope mapping flow cytometry gene mutation glycoproteins host organism interaction human subject hybridomas immunogenetics immunologic memory live vaccine organ culture shingles skin varicella zoster virus virus protein virus replication
项目摘要
Varicella-zoster virus (VZV) causes varicella and herpes zoster. Our goal is to improve knowledge about how this common pathogen causes disease and about protection provided by natural and vaccine-induced immunity. Glycoproteins are likely to be host range determinants for T cells and skin, which are critical target cells during VZV infection. Our focus is on glycoproteins, gI (ORF67) and gE (ORF68). The effect of gI or gE mutations made in cosmids, on VZV replication will be determined in vitro. Infectivity for human CD4+ and CD8+ T cells or skin will be assessed in vivo in the SCIDhu mouse model of VZV pathogenesis, which reveals critical roles for VZV proteins that are completely dispensable in tissue culture. T cell tropism will also be investigated in thymic organ cultures and II23 cells, a CD4+ T cell hybridoma, using green fluorescent protein (gfp)-labeled VZV. VZV gI and gE effects on epithelial cells will be evaluated in MDCK cells. The vaccine strain, V-Oka, will be compared with its parent, P-Oka, to determine whether gE or gI mutations explain V-Oka attenuation. VZV infects T cells in the naive host and spreads before VZV specific immunity is induced. We have found that VZV interferes with cell surface expression of major histocompatibility (MHC) class I and class II. Our goals are to identify viral immunomodulatory proteins that allow VZV to escape from immune surveillance and to determine whether skin homing receptors facilitate transport of infected T cells to skin. Whether these mechanisms function at skin sites during natural infection will be determined in biopsies from acute varicella lesions. Rapid acquisition of VZV specific T cell responses correlates with mild varicella and maintenance of latency. We propose to address important questions about adaptive VZV immunity with new methods to measure CD4+ and CD8+ T cell responder frequencies against dominant viral proteins, gE and the immediate early tegument/transactivating protein, IE62. We will examine differences in protection afforded by natural and vaccine-induced immunity, diminished immunogenicity of varicella vaccine in adults, and declining VZV T cell responses with aging. Quantitative comparisons of CD4+ and CD8+ recognition of gE and IE62 protein and peptides will be made using intracellular cytokine assays. Peptides appropriate for synthesis as MHC class I and class II tetramers will be identified and used to enumerate VZV specific responder T cells in CD4+ and CD8+ subsets. These parallel investigations of VZV pathogenesis and immunity are directly linked by their practical relevance for improving live attenuated varicella vaccines.
水痘-带状疱疹病毒(VZV)引起水痘和带状疱疹。我们的目标是提高对这种常见病原体如何引起疾病以及自然和疫苗诱导的免疫力提供的保护的认识。 糖蛋白可能是T细胞和皮肤的宿主范围决定因素,T细胞和皮肤是VZV感染期间的关键靶细胞。 我们的重点是糖蛋白,gI(ORF 67)和gE(ORF 68)。 将在体外确定在Cosmos中产生的gI或gE突变对VZV复制的影响。 将在VZV发病机制的SCIDhu小鼠模型中体内评估对人CD 4+和CD 8 + T细胞或皮肤的免疫活性,这揭示了在组织培养中完全粘附的VZV蛋白的关键作用。 还将使用绿色荧光蛋白(gfp)标记的VZV在胸腺器官培养物和II 23细胞(一种CD 4 + T细胞杂交瘤)中研究T细胞嗜性。 将在MDCK细胞中评价VZV gI和gE对上皮细胞的影响。 将疫苗株V-Oka与其亲本P-Oka进行比较,以确定gE或gI突变是否解释V-Oka减毒。 VZV感染初始宿主中的T细胞并在VZV特异性免疫被诱导之前传播。我们已经发现,VZV干扰细胞表面表达的主要组织相容性(MHC)I类和II类。 我们的目标是确定病毒免疫调节蛋白,使VZV逃脱免疫监视,并确定皮肤归巢受体是否促进受感染的T细胞运输到皮肤。 这些机制是否在自然感染期间在皮肤部位起作用将在急性水痘病变的活检中确定。 VZV特异性T细胞应答的快速获得与轻度水痘和潜伏期的维持相关。 我们建议解决适应性VZV免疫的重要问题,新的方法来测量CD 4+和CD 8 + T细胞应答频率对显性病毒蛋白,gE和立即早期皮层/反式激活蛋白,IE62。我们将研究自然和疫苗诱导的免疫所提供的保护差异,水痘疫苗在成人中的免疫原性降低,以及VZV T细胞应答随年龄增长而下降。将使用细胞内细胞因子测定对gE和IE62蛋白和肽的CD 4+和CD 8+识别进行定量比较。 将鉴定适于合成为MHC I类和II类四聚体的肽,并用于计数CD 4+和CD 8+亚群中的VZV特异性应答T细胞。 这些VZV发病机制和免疫的平行研究与其改善水痘减毒活疫苗的实际相关性直接相关。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ann Arvin其他文献
Ann Arvin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ann Arvin', 18)}}的其他基金
Varicella zoster virus: molecular controls of cell fusion-dependent pathogenesis
水痘带状疱疹病毒:细胞融合依赖性发病机制的分子控制
- 批准号:
8663185 - 财政年份:2012
- 资助金额:
$ 29.71万 - 项目类别:
Varicella zoster virus: molecular controls of cell fusion-dependent pathogenesis
水痘带状疱疹病毒:细胞融合依赖性发病机制的分子控制
- 批准号:
8472440 - 财政年份:2012
- 资助金额:
$ 29.71万 - 项目类别:
Varicella zoster virus: molecular controls of cell fusion-dependent pathogenesis
水痘带状疱疹病毒:细胞融合依赖性发病机制的分子控制
- 批准号:
8401103 - 财政年份:2012
- 资助金额:
$ 29.71万 - 项目类别:
Protective Immunity Against Herpesvirus Infections
针对疱疹病毒感染的保护性免疫
- 批准号:
8260368 - 财政年份:2011
- 资助金额:
$ 29.71万 - 项目类别:
Varicella-zoster Virus: Tegument Proteins in Pathogenesis
水痘带状疱疹病毒:发病机制中的皮层蛋白
- 批准号:
8121089 - 财政年份:2010
- 资助金额:
$ 29.71万 - 项目类别:
Investigation of herpes simplex virus -1 neurotropism in SCID DRG xenografts
SCID DRG 异种移植物中单纯疱疹病毒-1 向神经性的研究
- 批准号:
7638379 - 财政年份:2009
- 资助金额:
$ 29.71万 - 项目类别:
Investigation of herpes simplex virus -1 neurotropism in SCID DRG xenografts
SCID DRG 异种移植物中单纯疱疹病毒-1 向神经性的研究
- 批准号:
7847594 - 财政年份:2009
- 资助金额:
$ 29.71万 - 项目类别:
Pilot Projects Component (Pilot Proj 2: Guccione)
试点项目组件(试点项目 2:Guccione)
- 批准号:
7657168 - 财政年份:2008
- 资助金额:
$ 29.71万 - 项目类别:
Protective Immunity Against Herpesvirus Infections
针对疱疹病毒感染的保护性免疫力
- 批准号:
7212913 - 财政年份:2007
- 资助金额:
$ 29.71万 - 项目类别:
相似海外基金
Elucidating a molecular understanding of ILC2 MHC class I antigen cross priming
阐明 ILC2 MHC I 类抗原交叉引发的分子理解
- 批准号:
486527 - 财政年份:2022
- 资助金额:
$ 29.71万 - 项目类别:
Studentship Programs
Restoring MHC class I antigen presentation to enhance anti-tumour immunity
恢复MHC I类抗原呈递,增强抗肿瘤免疫力
- 批准号:
nhmrc : GNT1164054 - 财政年份:2020
- 资助金额:
$ 29.71万 - 项目类别:
Project Grants
Subversion of MHC class I antigen presentation by viral immunomodulatory proteins
病毒免疫调节蛋白颠覆 MHC I 类抗原呈递
- 批准号:
8996707 - 财政年份:2014
- 资助金额:
$ 29.71万 - 项目类别:
Ubiquitin conjugation and direct MHC class I antigen presentation
泛素结合和直接 MHC I 类抗原呈递
- 批准号:
8880646 - 财政年份:2014
- 资助金额:
$ 29.71万 - 项目类别:
Subversion of MHC class I antigen presentation by viral immunomodulatory proteins
病毒免疫调节蛋白颠覆 MHC I 类抗原呈递
- 批准号:
9206412 - 财政年份:2014
- 资助金额:
$ 29.71万 - 项目类别:
Subversion of MHC class I antigen presentation by viral immunomodulatory proteins
病毒免疫调节蛋白颠覆 MHC I 类抗原呈递
- 批准号:
8723605 - 财政年份:2014
- 资助金额:
$ 29.71万 - 项目类别:
MHC Class I Antigen Presentation in Viral Infections
病毒感染中 MHC I 类抗原呈递
- 批准号:
8072956 - 财政年份:2010
- 资助金额:
$ 29.71万 - 项目类别:
The function of the Ubiquitin-Proteasome-System (UPS) in MHC class I antigen processing in target cells and maturing human dendritic cells (hDCs).
泛素蛋白酶体系统 (UPS) 在靶细胞和成熟人树突细胞 (hDC) 中 MHC I 类抗原加工中的功能。
- 批准号:
105348415 - 财政年份:2009
- 资助金额:
$ 29.71万 - 项目类别:
Research Grants
In vivo analysis of the imnportance of proteasome immunosubunits and of PA28 for MHC class I antigen processing, CTL response induction and tumor-virus elimination (A 7)
体内分析蛋白酶体免疫亚基和 PA28 对于 MHC I 类抗原加工、CTL 反应诱导和肿瘤病毒消除的重要性 (A 7)
- 批准号:
5354871 - 财政年份:2002
- 资助金额:
$ 29.71万 - 项目类别:
Collaborative Research Centres
MHC Class I Antigen Presentation in Viral Infections
病毒感染中 MHC I 类抗原呈递
- 批准号:
7991835 - 财政年份:2001
- 资助金额:
$ 29.71万 - 项目类别: